Cardiac Science Reports Record Fourth Quarter and Full Year 20...( Fourth Quarter Revenue...),Health

Fourth Quarter Revenue up 29% to $50.4 Million

Strong Revenue Growth in both Defibrillation and Cardiac Monitoring

Full Year Revenue Growth of 17% to $182 Million and EPS of $0.37

BOTHELL, Wash., Feb. 28 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, today announced record results for the fourth quarter and full year ended December 31, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050913/SFTU139LOGO)

Revenue for the quarter was $50.4 million, an increase of 29% over the prior year period. The growth reflected an increase in defibrillation and cardiac monitoring sales of 48% and 16%, respectively. Domestic automated external defibrillator (AED) sales grew 30% from the prior year's fourth quarter, while international AED sales rose 68% for the quarter, driven by strong growth throughout Europe and Asia. The Company reported net income of $2.4 million, or $0.10 per diluted share in the fourth quarter, compared to a small net loss of $35,000, or $0.00 per share in the fourth quarter of 2006.

For the full year 2007, revenue totaled $182.1 million, an increase of 17% compared to revenue of $155.4 million for 2006. The Company reported net income of $8.5 million for the year, or $0.37 per diluted share. Net income for the year included a non-cash benefit and related cash expenses associated with litigation that was settled in 2007. Excluding these litigation-related items, pro forma net income would have been $7.1 million, or $0.31 per diluted share.

2007 Accomplish
'/>"/>